Spyre Therapeutics, Inc. (SYRE)
About Spyre Therapeutics, Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$155.2M
- Total assets
- $777.8M
- Market cap
- $6.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $209.6M
- Operating income
- -$209.6M
- Income tax
- -$15.0K
- Net income
- -$155.2M
Balance sheet
- Total assets
- $777.8M
- Current assets
- $777.8M
- Total liabilities
- $62.5M
- Current liabilities
- $58.7M
- Shareholders’ equity
- $715.2M
Cash flow
- Operating cash flow
- -$169.3M
- Investing cash flow
- -$143.5M
- Financing cash flow
- $309.0M
- Net cash flow
- -$3.7M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year · hover for prices
52-week range
- Market cap
- $6.4B
- Shares outstanding
- 62.6M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 7, 2016
Spyre Therapeutics, Inc. (SYRE) Stock Price
- Reported a net loss of $155.2M in FY2025.
- Trading near its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Spyre Therapeutics, Inc..
Write a review
News about Spyre Therapeutics, Inc.
News & sentiment via Polygon.io
Spyre Therapeutics, Inc.: frequently asked questions
Is Spyre Therapeutics, Inc. an American company?
Spyre Therapeutics, Inc. is a US-based company headquartered in Waltham, Massachusetts, listed in the americancompanies.com directory of American companies. Its American-origin credentials have not yet been independently verified.
Where is Spyre Therapeutics, Inc. headquartered?
Spyre Therapeutics, Inc. is headquartered in Waltham, Massachusetts, United States.
Is Spyre Therapeutics, Inc. publicly traded?
Yes — Spyre Therapeutics, Inc. is a publicly traded company. Its stock trades under the ticker symbol SYRE on the NASDAQ.
What does Spyre Therapeutics, Inc. do?
Spyre Therapeutics, Inc. is an American Pharmaceuticals company in the Health & Beauty sector.
